麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida鈥檚 KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida鈥檚 KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Apr 27 2016

Full Issue

Perspectives On Drug Prices: Neediest Patients Aren't Seeing Benefits From Rebates

A selection of opinions on drug costs from around the country.

American spending on retail prescription drugs hit $425 billion, according to a report by the IMS Institute for Healthcare Informatics. That, and year-over-year growth of around 12 percent is likely to capture headlines. But dig a little deeper and you鈥檒l find that rebates and other discounts that pharmaceutical companies offer insurers slashed that spending to $310 billion. For patent-protected-drugs this is especially important 鈥 these price concessions cut price growth by between 77 and 81 percent. That鈥檚 great news for the health care system and for insurers 鈥 but unfortunately, the neediest patients with the highest costs don鈥檛 benefit much from these concessions. That鈥檚 due for a change. (Yevgenity Feyman, 4/26)

Read the headlines these days and you鈥檇 think the health insurance companies are going broke. It鈥檚 true most insurers offering Obamacare are losing money on it. UnitedHealth Group, the nation鈥檚 largest insurer, announced it will all but exit Obamacare next year because of those loses. But insurance companies have not fallen on hard times. Anything but. (Paul Alexander, 4/25)

No argument against the proposed Trans-Pacific Partnership trade agreement packs more emotional punch than the claim that the deal would be bad for people's health 鈥 and even result in avoidable deaths 鈥 both in the United States and in the 11 other signatory nations. The argument, repeated most recently in a letter to Congress from the U.S. branches of Doctors Without Borders, Oxfam America and about 50 other organizations, is that the TPP would unduly extend U.S. patent and intellectual property protections for the pharmaceutical industry, thus driving up prices for lifesaving medicines. In fact, the letter argues, the "TPP would do more to undermine access to affordable medicines than any previous U.S. trade agreement." (4/26)

Medicare drug plans are governed by federal law. But for the rest of us with a drug plan, the state in which we reside generally regulates drug plans and pharmacy benefits. When pharmacists descend on state capitols they often find a sympathetic ear in state legislators. (Devon Herrick)

Humans have been 鈥渞epurposing鈥 for centuries. Today we turn old churches into museums, schoolhouses into condos, old tires into artificial turf, and plastic bottles into dress pants. Drugs have become a new and exciting target for this activity. Two high-profile examples in the drug world are sildenafil and minoxidil. Both began as medications for cardiovascular issues. But along the way, it became clear that they did other things even better. Sildenafil, rebranded as Viagra, helps some men with erectile dysfunction get and sustain erections. Minoxidil helps hair grow, which spawned Rogaine. (David E. Potter, 4/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优